The primary aim of the study is to generate a cohort, which provides information on sex- and gender differences in: prevalence and incidence of (clinically relevant clusters of) PFS, risk factors and prognostic factors for PFS, factors that reveal…
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
pelvic floor disorders
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
To evaluate the sex- and gender difference in prevalence and incidence of
(clinically relevant clusters of) PFS, the following primary parameters are
assessed: lower urinary tract symptoms, bowel symptoms, prolapse (in women
only), sexual functioning, and pain.
Secondary outcome
Secondary study parameters are factors associated with the development of PFS
(*risk factors*), factors that predict the course of PFS (*prognostic
factors*), factors that reveal the impact of PFS on daily life, help seeking
behavior, and health care use (consultations for PFS and consultation
frequency, diagnostic tests, diagnoses, treatment, and referrals).
Background summary
Pelvic floor symptoms (PFS) are prevalent and often impair quality of life.
They include micturition problems, defecation problems, pelvic organ prolapse,
sexual problems and genito-pelvic pain. The pelvic floor is an anatomical and
functional unit, and therefore different PFS may co-occur. However, literature
on prevalence of clusters of PFS is scarce. Furthermore, PFS is understudied in
the male population and when studies are performed in male subjects, studies do
not assess the complete scope of possible PFS. Currently, different secondary
care specialists treat PFS. This may lead to successive diagnostic tests,
sub-optimal treatments, high patient burden, and substantial medical costs.
Primary care would be an ideal setting for an integrated approach early in the
course of symptom development in order to prevent complexity and chronicity of
PFS.
Study objective
The primary aim of the study is to generate a cohort, which provides
information on sex- and gender differences in: prevalence and incidence of
(clinically relevant clusters of) PFS, risk factors and prognostic factors for
PFS, factors that reveal the impact of PFS on daily life, help seeking behavior
and use of health care.
Study design
A prospective observational population-based cohort study will be conducted
with follow-up moments after 1 year and 2 years. Data of the questionnaire will
be connected to medical record data from the participating general
practitioners (GPs). A representative sample of female and male subjects with
and without PFS will be invited for a physical examination to assess pelvic
floor disorders and muscle function. Furthermore, a subsample of patients will
be invited for a qualitative study consisting of semi-structured interviews on
help seeking behavior, including barriers and facilitators, preferences and
satisfaction.
Study burden and risks
Participants have to fill in a questionnaire consisting of eleven parts for
female subjects and ten parts for male subjects. The total time to complete the
questionnaire will be around 45-60 minutes. As some questions will be on
personal, intimate and sexual items, participants might feel uncomfortable
filling in those questions. Otherwise, burden of filling in the questionnaire
is negligible. Subjects, who provided specific informed consent for sub-study,
will undergo additional research consisting of approximately 20 minutes in case
of physical examination and 60 minutes in case of an interview.
Oostersingel, gebouw 50, 2e verdieping ingang 47
Groningen 9700 AD
NL
Oostersingel, gebouw 50, 2e verdieping ingang 47
Groningen 9700 AD
NL
Listed location countries
Age
Inclusion criteria
16 years or older
Exclusion criteria
• terminal disease
• dementia precluding informed consent
• cognitive impairment precluding informed consent
• current psychological condition precluding informed consent
• not suitable or too ill to participate based on the judgement of the general practitioner.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
ClinicalTrials.gov | NCT03558802 |
CCMO | NL67503.042.18 |